Have a personal or library account? Click to login
Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic – Do We Have the Evidence? Cover

Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic – Do We Have the Evidence?

Journal of Interdisciplinary Medicine
Volume 5 (2020): Issue 3 (September 2020)
By: Emanuel Blîndu,  Renata Gerculy,  Diana Opincariu,  Daniel Cernica and  Imre Benedek  
Open Access
|Oct 2020

References

  1. 1. SARS (Severe Acute Respiratory Syndrome). Available at: https://www.who.int/ith/diseases/sars/en/
    Search in Google ScholarBack to article
  2. 2. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. Available at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/
    Search in Google ScholarBack to article
  3. 3. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/
    Search in Google ScholarBack to article
  4. 4. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015-1018.10.1016/S0140-6736(20)30673-5
    Search in Google ScholarBack to article
  5. 5. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.10.1016/S2213-2600(20)30116-8
    Search in Google ScholarBack to article
  6. 6. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781-782.
    Search in Google ScholarBack to article
  7. 7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.10.1056/NEJMoa2002032709281932109013
    Search in Google ScholarBack to article
  8. 8. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776.10.1001/jama.2020.468332203977
    Search in Google ScholarBack to article
  9. 9. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.10.1056/NEJMoa2007621720693132356626
    Search in Google ScholarBack to article
  10. 10. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.
    Search in Google ScholarBack to article
  11. 11. Richardson S, Hirsch JS, Narasimhan M, el al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052-2059.10.1001/jama.2020.6775717762932320003
    Search in Google ScholarBack to article
  12. 12. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201-1228.10.1002/cphy.c130040413791224944035
    Search in Google ScholarBack to article
  13. 13. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281-2290.10.1152/ajpheart.00618.2005720356616055515
    Search in Google ScholarBack to article
  14. 14. Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation. 2020. [Epub ahead of print]10.1161/CIRCULATIONAHA.120.04704932213097
    Search in Google ScholarBack to article
  15. 15. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.10.1016/j.cell.2020.02.052710262732142651
    Search in Google ScholarBack to article
  16. 16. Matsuyama S, Nagata N, Shirato K, Kuwase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658-12660.10.1128/JVI.01542-10300435120926566
    Search in Google ScholarBack to article
  17. 17. Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoSOne. 2012;7:e35876.10.1371/journal.pone.0035876334040022558251
    Search in Google ScholarBack to article
  18. 18. South, AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305-307.10.1038/s41581-020-0279-4711870332246101
    Search in Google ScholarBack to article
  19. 19. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-876.10.1038/nm1267709578316007097
    Search in Google ScholarBack to article
  20. 20. Ocaranza MP, Godoy I, Jalil JE. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat. Hypertension. 2006;48:572-578.10.1161/01.HYP.0000237862.94083.4516908757
    Search in Google ScholarBack to article
  21. 21. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism. Hypertension. 2014;64:1368-1375.10.1161/HYPERTENSIONAHA.114.03743423188325225202
    Search in Google ScholarBack to article
  22. 22. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.10.1038/nature03712709499816001071
    Search in Google ScholarBack to article
  23. 23. Crackower M, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.10.1038/nature0078612075344
    Search in Google ScholarBack to article
  24. 24. Huentelman MJ, Grobe JL, Vazquez J. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790.10.1113/expphysiol.2005.03109616049057
    Search in Google ScholarBack to article
  25. 25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976.10.1161/01.HYP.0000124667.34652.1a15007027
    Search in Google ScholarBack to article
  26. 26. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.10.1097/00004872-199606000-000178793704
    Search in Google ScholarBack to article
  27. 27. Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin–angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71:539-570.10.1124/pr.118.017129678202331537750
    Search in Google ScholarBack to article
  28. 28. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.10.1074/jbc.M00261520010924499
    Search in Google ScholarBack to article
  29. 29. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Resp J. 2008;31:611-617.10.1183/09031936.0016200617959631
    Search in Google ScholarBack to article
  30. 30. Christopher H, Manaf Z, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Baylor University Medical Center Proceedings. 2018;31:419-423.10.1080/08998280.2018.1499293641400130948970
    Search in Google ScholarBack to article
  31. 31. Yang G, Tan Z, Zhou L, et al. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. medRxiv. 2020. [Epub ahead of print]10.1101/2020.03.31.20038935
    Search in Google ScholarBack to article
  32. 32. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. EmergMicrob Infect. 2020;9:757-760.10.1080/22221751.2020.1746200717036832228222
    Search in Google ScholarBack to article
  33. 33. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;NEJMoa2006923.10.1056/NEJMoa2006923720693332356627
    Search in Google ScholarBack to article
  34. 34. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;NEJMoa2008975.10.1056/NEJMoa2008975720693232356628
    Search in Google ScholarBack to article
  35. 35. Mehta M, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e210855.10.1001/jamacardio.2020.1855720137532936273
    Search in Google ScholarBack to article
  36. 36. de Abajo FJ, Rodriguez-Martin S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case population study. Lancet. 2020;395:1705-1714.10.1016/S0140-6736(20)31030-8
    Search in Google ScholarBack to article
  37. 37. Khera R, Clark C, Lu Y, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with Coronavirus Disease-19. medRxiv. 2020;20104943.10.1101/2020.05.17.20104943727324932511481
    Search in Google ScholarBack to article
  38. 38. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950.10.1001/jamacardio.2020.0950709784132211816
    Search in Google ScholarBack to article
  39. 39. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.10.1001/jama.2020.1585704288132031570
    Search in Google ScholarBack to article
  40. 40. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 13 Mar 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-onhypertension-on-ace-inhibitors-and-ang
    Search in Google ScholarBack to article
  41. 41. American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/jim-2020-0022 | Journal eISSN: 2501-8132 | Journal ISSN: 2501-5974
Journal RSS Feed
Language: English
Page range: 105 - 109
Submitted on: Jul 17, 2020
|
Accepted on: Aug 15, 2020
|
Published on: Oct 20, 2020
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
COVID-19,
ACE2,
angiotensin-1-7,
RAS inhibitors
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Internal medicine,
Internal medicine, other,
Surgery,
Surgery, other,
Emergency medicine and intensive-care medicine

© 2020 Emanuel Blîndu, Renata Gerculy, Diana Opincariu, Daniel Cernica, Imre Benedek, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 5 (2020): Issue 3 (September 2020)Next article